Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders

Fibroblast growth factor (FGF) 21 is a member of the endocrine FGF subfamily. FGF21 expression is induced under different disease conditions, such as type 2 diabetes, obesity, chronic kidney diseases, and cardiovascular diseases, and it has a broad spectrum of functions in regulating various metabolic parameters. Many different approaches have been pursued targeting FGF21 and its receptors to develop therapeutics for treating type 2 diabetes and other aspects of metabolic conditions. In this article, we summarize some of these key approaches and highlight the potential challenges in the development of these agents.

• Publication year

  2015

• Venue

  Frontiers in Endocrinology

• Publication date

  2015-11-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fendo.2015.00168PMID 26594197PMCID 4633491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening

  2015cited by this paper
• Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.

  2015cited by this paper
• Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex

  2015cited by this paper
• Fibroblast growth factor 21 protects the heart from oxidative stress.

  2015cited by this paper
• Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.

  2015cited by this paper
• Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes

  2015cited by this paper
• Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1.

  2015cited by this paper
• Serum FGF21 levels are associated with brown adipose tissue activity in humans

  2015cited by this paper
• Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis

  2014cited by this paper
• Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome.

  2014cited by this paper
• Monoclonal Antibody Targeting of Fibroblast Growth Factor Receptor 1c Ameliorates Obesity and Glucose Intolerance via Central Mechanisms

  2014cited by this paper
• Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice

  2014cited by this paper
• The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target

  2014cited by this paper
• Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.

  2014cited by this paper
• Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer

  2014influential reference
• A nontumorigenic variant of FGF19 treats cholestatic liver diseases

  2014cited by this paper
• Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction

  2014cited by this paper
• FGF21-based pharmacotherapy--potential utility for metabolic disorders.

  2014cited by this paper
• Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors

  2013cited by this paper
• Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.

  2013cited by this paper
• Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia

  2013cited by this paper
• Mild cold exposure modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans: relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis.

  2013cited by this paper
• An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.

  2013cited by this paper
• LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

  2013cited by this paper
• FGF21 contributes to neuroendocrine control of female reproduction

  2013cited by this paper
• Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.

  2013cited by this paper
• Development of a Novel Long-Acting Antidiabetic FGF21 Mimetic by Targeted Conjugation to a Scaffold Antibody

  2013cited by this paper
• The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.

  2013influential reference
• Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.

  2013cited by this paper
• Fibroblast growth factor 21 protects against cardiac hypertrophy in mice

  2013influential reference
• FGF21 regulates metabolism and circadian behavior by acting on the nervous system

  2013cited by this paper
• FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/β-Klotho Bispecific Protein

  2013cited by this paper
• The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue.

  2013cited by this paper
• Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities.

  2013cited by this paper
• Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

  2013cited by this paper
• Inventing new medicines: The FGF21 story☆

  2013cited by this paper
• Fibroblast growth factor receptors, developmental corruption and malignant disease.

  2013cited by this paper
• High Glucose Represses β-Klotho Expression and Impairs Fibroblast Growth Factor 21 Action in Mouse Pancreatic Islets

  2013cited by this paper
• Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.

  2013cited by this paper
• A Novel Approach to Improve the Function of FGF21

  2013cited by this paper
• Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

  2012cited by this paper
• Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques.

  2012cited by this paper
• A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis

  2012cited by this paper
• Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

  2012influential reference
• Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes.

  2012cited by this paper
• FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

  2012cited by this paper
• Conversion of a Paracrine Fibroblast Growth Factor into an Endocrine Fibroblast Growth Factor*

  2012cited by this paper
• Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism

  2012cited by this paper
• Circulating fibroblast growth factors as metabolic regulators--a critical appraisal.

  2012cited by this paper
• βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism.

  2012cited by this paper
• Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/FGFR1c Receptor Complex

  2012influential reference
• A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho.

  2012cited by this paper
• [Optimization and characterization of a novel FGF21 mutant].

  2012cited by this paper
• Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.

  2012cited by this paper
• Klotho Coreceptors Inhibit Signaling by Paracrine Fibroblast Growth Factor 8 Subfamily Ligands

  2012cited by this paper
• Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ

  2012cited by this paper
• The starvation hormone, fibroblast growth factor-21, extends lifespan in mice

  2012cited by this paper
• Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

  2012cited by this paper
• FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice

  2012cited by this paper
• Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities.

  2012cited by this paper
• Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

  2012cited by this paper
• Fibroblast Growth Factor 21 (FGF21) Inhibits Chondrocyte Function and Growth Hormone Action Directly at the Growth Plate

  2012cited by this paper
• Association between serum fibroblast growth factor 21 and diabetic nephropathy.

  2012cited by this paper
• FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis.

  2012cited by this paper
• Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose Tissue*

  2011cited by this paper
• A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (rhFGF21) Modified with Polyethylene Glycol

  2011cited by this paper
• Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease.

  2011cited by this paper
• Circulating FGF21 Levels Are Progressively Increased from the Early to End Stages of Chronic Kidney Diseases and Are Associated with Renal Function in Chinese

  2011cited by this paper
• Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo.

  2011cited by this paper
• FGF21 reloaded: challenges of a rapidly growing field.

  2011cited by this paper
• Hormone-like fibroblast growth factors and metabolic regulation.

  2011cited by this paper
• Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1

  2011influential reference
• Brown Adipose Tissue Responds to Cold and Adrenergic Stimulation by Induction of FGF21

  2011cited by this paper
• FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways

  2011cited by this paper
• Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease

  2010cited by this paper
• Fibroblast growth factor 21: from pharmacology to physiology.

  2010cited by this paper
• Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.

  2010influential reference
• Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

  2010cited by this paper
• Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile

  2010cited by this paper
• Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

  2010influential reference
• Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)

  2010cited by this paper
• Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity.

  2009cited by this paper
• Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity

  2009cited by this paper
• Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

  2009cited by this paper
• Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice

  2009cited by this paper
• Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis.

  2009cited by this paper
• FGF21 N‐ and C‐termini play different roles in receptor interaction and activation

  2009cited by this paper
• Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

  2009cited by this paper
• Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects.

  2009cited by this paper
• Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

  2009cited by this paper
• FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation

  2009cited by this paper
• Different roles of N‐ and C‐ termini in the functional activity of FGF21

  2009cited by this paper
• Fibroblast growth factor 21 corrects obesity in mice.

  2008cited by this paper
• FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

  2008cited by this paper
• C-terminal Tail of FGF19 Determines Its Specificity toward Klotho Co-receptors*

  2008cited by this paper
• Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

  2008cited by this paper
• FGF21 attenuates lipolysis in human adipocytes – A possible link to improved insulin sensitivity

  2008cited by this paper
• Inhibition of growth hormone signaling by the fasting-induced hormone FGF21.

  2008cited by this paper
• betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c.

  2008cited by this paper
• PPARα is a key regulator of hepatic FGF21

  2007cited by this paper

• Advances in the Pharmacologic Management of MASLD

  2026cites this paper
• Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis.

  2025cites this paper
• Multimodal Therapeutic Strategies Targeting BCAA Metabolism in Diabetic Cardiomyopathy: A Path to Cardioprotection

  2025cites this paper
• The Metabolic Transition Between Fasting and Feeding Alters Aging‐Associated Metabolites, Lowers BCAAs, and Stimulates FGF21 Production in Humans

  2025cites this paper
• A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control

  2025cites this paper
• Pegbelfermin for reducing transaminase levels in patients with non-alcoholic steatohepatitis: a dose-response meta-analysis of randomized controlled trials

  2024cites this paper
• FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond.

  2024cites this paper
• AAV2-mediated ABD-FGF21 gene delivery produces a sustained anti-hyperglycemic effect in type 2 diabetic mouse.

  2024cites this paper
• Prevalence of metabolic dysfunction–associated fatty liver disease among patients with diabetic kidney disease: a systematic review and meta-analysis

  2024cites this paper
• Evaluating Fibroblast Growth Factor 21 (FGF21) Levels Post-Gastric Sleeve Surgery in Obese Patients

  2024cites this paper
• Plasma FGF21 Concentration in Kidney Transplant Patients—Results from Prospective and Cross-Sectional Studies

  2024influential citation
• The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise

  2023cites this paper
• The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review

  2023cites this paper
• The Novel Tetra-Specific Drug C-192, Conjugated Using UniStac, Alleviates Non-Alcoholic Steatohepatitis in an MCD Diet-Induced Mouse Model

  2023cites this paper
• Fibroblast growth factor 21 in metabolic syndrome

  2023cites this paper
• BRAIDing receptors for cell-specific targeting

  2023cites this paper
• A human laboratory study on the link between alcohol administration and circulating fibroblast growth factor 21 (FGF21) in individuals with alcohol use disorder.

  2023cites this paper
• The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model

  2022cites this paper
• Endocrine manifestations of chronic kidney disease and their evolving management: A systematic review.

  2022cites this paper
• Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression

  2022cites this paper
• High circulating fibroblast growth factor-21 levels as a screening marker in fatty pancreas patients

  2022cites this paper
• Multi-organ FGF21-FGFR1 signaling in metabolic health and disease

  2022cites this paper
• Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies

  2021cites this paper
• MiniCAFE, a CRISPR/Cas9-based compact and potent transcriptional activator, elicits gene expression in vivo

  2021cites this paper
• Lipid Disorders in NAFLD and Chronic Kidney Disease

  2021cites this paper
• Regulation and Potential Biological Role of Fibroblast Growth Factor 21 in Chronic Kidney Disease

  2021cites this paper
• Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice

  2021cites this paper
• Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches

  2020cites this paper
• FGF21 Protects Dopaminergic Neurons in Parkinson’s Disease Models Via Repression of Neuroinflammation

  2020cites this paper
• Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction?

  2019cites this paper
• Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases

  2019cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.

  2019cites this paper
• Circulating FGF21 Levels in Human Health and Metabolic Disease.

  2019cites this paper
• Association between circulating fibroblast growth factor 21, aerobic fitness, and aortic blood pressure in middle-aged and older women

  2019cites this paper
• The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients

  2019cites this paper
• A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling

  2018cites this paper
• A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity

  2018cites this paper
• Fetal programming of adult disease: causes and consequences of metabolic dysregulation in an ovine model of PCOS

  2018cites this paper
• An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity

  2018cites this paper
• Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women

  2018cites this paper
• Recombinant FGF21 Protects Against Blood-Brain Barrier Leakage Through Nrf2 Upregulation in Type 2 Diabetes Mice

  2018cites this paper
• Endocrine Regulator rFGF21 (Recombinant Human Fibroblast Growth Factor 21) Improves Neurological Outcomes Following Focal Ischemic Stroke of Type 2 Diabetes Mellitus Male Mice

  2018cites this paper
• Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease

  2018cites this paper
• Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

  2018cites this paper
• Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance

  2018cites this paper
• FGF21 gene therapy as treatment for obesity and insulin resistance

  2018cites this paper
• Thyroid Hormone-Induced Expression of the Hepatic Scaffold Proteins Sestrin2, β-Klotho, and FRS2α in Relation to FGF21-AMPK Signaling.

  2017cites this paper
• Fibroblast growth factor 21 night watch: advances and uncertainties in the field

  2017cites this paper
• Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease

  2017cites this paper
• The role of fibroblast growth factor 21 in atherosclerosis.

  2017cites this paper
• Fibroblast Growth Factor 21—Metabolic Role in Mice and Men

  2017cites this paper
• FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice

  2017cites this paper
• Open Peer Review

  2016cites this paper
• A Fibroblast Growth Factor 21 – Pregnane X Receptor Pathway Downregulates Hepatic Cytochrome P 450 3 A 4 in Nonalcoholic Fatty Liver Disease

  2016cites this paper
• Regulation of myokine expression: Role of exercise and cellular stress.

  2016cites this paper
• A Fibroblast Growth Factor 21–Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease

  2016cites this paper
• Hepatokines and non-alcoholic fatty liver disease.

  2016cites this paper
• Hepatokines and non-alcoholic fatty liver disease

  2016cites this paper
• Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities

  2016cites this paper
• Macronutrient Intake–Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial

  2016cites this paper
• Finding Ponce de Leon’s Pill: Challenges in Screening for Anti-Aging Molecules

  2016cites this paper
• [Fibroblast growth factor 21 - current point of view on its role in physiology of the organism and the pathogenesis of diabetes mellitus and obesity].

  2015cites this paper
• The future of diabetes.

  2015cites this paper
• Fatty liver and chronic kidney disease : novel mechanistic insights and therapeutic opportunities Running title : NAFLD and CKD

  year unknowncites this paper